Repeated complete responses with bortezomib in a heavily pretreated primary refractory patient with light chain multiple myeloma

Clinical Lymphoma and Myeloma

Volumn 7, Issue 5, 2007, Pages 373-375

  Bhandari, Meghana ^a   Jagannath, Simdar ^a  

^a ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Bence Jones protein; Proteasome inhibitors; Retreatment; Targeted therapy

Indexed keywords

BENCE JONES PROTEIN; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; ADVANCED CANCER; ALBUMINURIA; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CASE REPORT; CELL INFILTRATION; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; FEMALE; HUMAN; HYPERESTHESIA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; PERIORBITAL EDEMA; PLASMA CELL; PROTEINURIA; RASH; TREATMENT RESPONSE; VOMITING;

EID: 34248214789     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2007.n.016     Document Type: Article

References (9)

1. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
2. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165-172.
3. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-2498.
4. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102:1115-1123.
5. Conner TM, Doan QD, Leblanc AL, et al. An observational, retrospective analysis of retreatment with bortezomib of multiple myeloma (MM) patients. Blood 2006; 108:1007a (Abstract #3531).
6. Sood R, Carloss H, Kerr R, et al. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib: a phase IV, open-label trial. Ann Oncol 2006; 17(suppl 9):ix196:ix212 (Abstract #679P).
7. Wolf JL, Richardson P, Schuster M, et al. Utility of bortezomib retreatment for patients with relapsed multiple myeloma. Blood 2006; 108:1008a (Abstract #3532).
8. Berenson JR, Jagannath S, Barlogie B, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005; 104:2141-2148.
9. The Evaluation of Velcade® Employed as Retreatment for Efficacy, Safety, and Tolerability [Web site]. Available at: http://multiplemyeloma.org/ clinical_trials/ctm/4.04.171.html. Accessed August 11, 2006.